This week, we published our Annual Report for the 2022/23 financial year, and I couldn’t be more excited to reflect on such a momentous year for progress, both in dementia research and at Alzheimer’s Research UK.
Our Chief Executive Hilary Evans reflects on the changing outlook for dementia research, and why it’s time to strive for a cure.
Your support is continuing to fund research like this that will make our mission to bring about a life-changing dementia treatment for people possible.
As we all adapt to a temporary, extraordinary new way of living, we wanted to update you on how we’re adapting at Alzheimer’s Research UK, and the potential impact of COVID-19 on dementia research.
The COVID-19 Symptom Tracker app, developed by King’s College London, is joining forces with the UK’s largest health-based charities. The aim is to reach people most at risk of COVID-19, including those with pre-existing health conditions such as dementia, diabetes, heart disease and those over the age of 70.
People with dementia are likely to be particularly vulnerable to this virus so it is especially important that they and those around them take what steps they can to avoid transmission.
We’re acutely aware of the impact the outbreak will be having on people with dementia and their families, exacerbating an already unprecedented situation. Our hearts go out to everyone in such circumstances.
The Early Detection of Neurodegenerative diseases (EDoN) initiative is spearheaded by Alzheimer’s Research UK and brings together 14 leading research and support organisations, working to develop innovative ways to pick up these diseases in the brain years before the symptoms of dementia start.